Obesity management: update on orlistat. (Q36596807)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18200802%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

review article

1 reference

title

Obesity management: update on orlistat (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18200802%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

3 references

19 March 2019

24 March 2019

11 November 2019

1 reference

11 November 2019

3

John B Dixon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18200802%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Belinda S Drew

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18200802%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Andrew F Dixon

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18200802%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

language of work or name

English

0 references

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18200802%20AND%20SRC:MED&resulttype=core&format=json

Vascular Health and Risk Management

1 January 2020

published in

4 references

19 March 2019

24 March 2019

11 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18200802%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18200802%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

817-821

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18200802%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18200802%20AND%20SRC:MED&resulttype=core&format=json

Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

1 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Long-term non-pharmacological weight loss interventions for adults with type 2 diabetes mellitus

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Long-term pharmacotherapy for obesity and overweight.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Effects of Orlistat, a Lipase Inhibitor, on the Pharmacokinetics of Three Highly Lipophilic Drugs (Amiodarone, Fluoxetine, and Simvastatin) in Healthy Volunteers

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Lipid profile in the severely obese: changes with weight loss after lap-band surgery

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Orlistat: selective inhibition of caloric absorption can affect long-term body weight

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Results from the observational study EPIGRAM: management of excess weight in general practice and follow-up of patients treated with orlistat

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Orlistat enhances warfarin effect

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Effects of orlistat on fat-soluble vitamins in obese adolescents

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Orlistat inhibits dietary cholesterol absorption

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2350121

20 September 2018

1 reference

12 December 2020

A disparity between conventional lipid and insulin resistance markers at body mass index levels greater than 34 kg/m(2)

1 reference

12 December 2020

Influence of orlistat on bone turnover and body composition

1 reference

12 December 2020

Beneficial health effects of modest weight loss

1 reference

12 December 2020

Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers

1 reference

12 December 2020

A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease

1 reference

12 December 2020

[Use of orlistat (xenical) in the treatment of women with obesity and disorders of menstrual cycle]

1 reference

12 December 2020

Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor

1 reference

12 December 2020

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

1 reference

12 December 2020

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18200802%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference